このエピソードについて
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
英語
アメリカ合衆国
過去のエピソードを検索
FDA CDER Small Business and Industry Assistance (SBIA) Chroniclesの以前のエピソードを検索します。
このポッドキャストの他のエピソード
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
免責: このページに埋め込まれているポッドキャストとアートワークは U.S. Food and Drug Administration, Center for Drug Evaluation and Research からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
